Amir Nashat

Amir is a managing partner in Polaris’ Boston office. He joined Polaris in 2002 and focuses on investments in healthcare.

Amir currently represents Polaris as a Director of AgBiome, CAMP4 Therapeutics, Dewpoint Therapeutics, Metacrine Therapeutics, Morphic Therapeutic (NASDAQ: MORF), Primmune Therapeutics, Scholar Rock (NASDAQ: SRRK), and Syros Pharmaceuticals (NASDAQ: SYRS). Additionally, Amir has served as a director of Adnexus Therapeutics (Bristol Myers Squibb), Athenix Corporation (Bayer), Avila Therapeutics (Celgene), Fate Therapeutics (NASDAQ: FATE), Freenome, Living Proof (Unilever), Promedior Pharmaceuticals, Receptos (Celgene), Selecta Biosciences (NASDAQ: SELB), Sun Catalytix (Lockheed Martin), and TARIS Biomedical (J&J).

In addition to his investment role, Amir has served as the CEO of Dewpoint, Jnana, Living Proof, Olivo Labs, and Sun Catalytix. Amir also serves on the Partners Innovation Fund and the Investment Advisory Committee for The Engine at MIT, and helped launch the MIT Sandbox Innovation Fund as its active president.

He has been named to the Forbes Midas List of “Top 100 Venture Capitalists.”

Prior to joining Polaris, Amir completed his ScD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. Amir also earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley.